Fig. 4: The 95 NLS gene signatures stratify prostate cancer with neuroendocrine differentiation from prostate adenocarcinoma. | Communications Medicine

Fig. 4: The 95 NLS gene signatures stratify prostate cancer with neuroendocrine differentiation from prostate adenocarcinoma.

From: Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes

Fig. 4

a Hierarchical cluster of neural lineage signature genes in Wassim small-cell cohorts. Pathology classification (small cell, adenocarcinoma with neuroendocrine (NE) features, adenocarcinoma, not available and inadequate for the diagnosis) are indicated in the annotation track next to the heatmap. b GSEA enrichment plots for neural lineage signature in small cell and adenocarcinoma with NE feature groups with NES and FDR q values shown. c Hierarchical cluster heatmap of neural lineage signature genes in Labrecque cohorts. Molecular characteristic classification (AR high (ARPC), AR low (ARLPC), amphicrine expression of both AR and NE markers (AMPC), double-negative expression of both AR and NE markers (DNPC), and small-cell neuroendocrine SCNPC) are indicated in the annotation track next to the heatmap. d GSEA enrichment plots of neural lineage signature genes in Labrecque cohorts with NES score and FDR q values. NLS neural lineage signature, GSEA Gene Set Enrichment Analysis. *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page